Although accumulating evidence suggests the presence of microbleeds as a risk factor for intracerebral hemorrhage (ICH), little is known about its significance in anticoagulated patients. The aim of this study was to determine whether the presence of microbleeds is associated with recurrent hemorrhagic stroke in patients who had received warfarin following atrial fibrillation-associated cardioembolic infarction.
O
ne of the major complications of warfarin treatment following atrial fibrillation-related cardioembolic infarction is the occurrence of intracerebral hemorrhage (ICH). With advancing age, the incidence of both atrial fibrillation-related cardioembolic infarction and warfarin-related ICH increases.
Cerebral microbleeds detected by gradient-echo T2*-weighted MR imaging, which are shown as signal-intensity loss, represent hemosiderin deposit 1, 2 and are associated with occurrence of ICH. [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] Although accumulating evidence suggests that the presence of microbleeds is a risk factor for ICH in patients treated by antiplatelet therapy 13, 20 and hemorrhagic complications of anticoagulation in patients with prior ICH and atrial fibrillation have been reported, 21 little is known about the significance of microbleeds in anticoagulated patients because, to our knowledge, no studies have focused on the association between cerebral microbleeds and anticoagulation therapy in a large number of patients. On the other hand, previous studies focusing on radiographic characteristics have shown that the presence of microangiopathy (leukoaraiosis) detected by CT is a risk factor for warfarin-related ICH. 22 However, considering the close association between cerebral microbleeds and leukoaraiosis (white matter hyperintensity [WMH]), 7, 8, 11, [14] [15] [16] 19, 23, 24 one could hypothesize that cerebral microbleeds, which represent bleeding from small vessels, may be more closely associated with ICH than WMH is. Therefore, the present study was performed to determine whether the presence of microbleeds is associated with recurrent hemorrhagic stroke in patients who have received warfarin treatment following atrial fibrillation-associated cardioembolic infarction.
Materials and Methods
We prospectively evaluated inpatients with acute recurrent stroke who had received warfarin treatment following nonvalvular atrial fibrillation-associated cardioembolic infarction and who had undergone MR imaging studies in our hospital during the period from September 2002 to August 2007. Patients with valvular infarcts were excluded because they might have received a different anticoagulation regimen, and patients with arterial-origin infarcts were also excluded because they might not have been anticoagulated. Patients with hemorrhagic stroke or hemorrhagic conversion of the initial infarction were also excluded. Diagnosis of acute recurrent stroke was made on the basis of neurologic signs and symptoms and results of neuroradiologic examinations. Stroke was classified into ICH and ischemic stroke. ICH was diagnosed by CT, and acute ischemic stroke was confirmed by diffusion-weighted imaging (DWI) and apparent diffusion coefficient maps.
All patients were examined by using a 1.5T clinical MR imaging unit (Magnetom Symphony; Siemens, Erlangen, Germany), and the whole brain was scanned with a section thickness of 5 mm and a 1. Microbleeds were defined as homogeneous round signal-intensity-loss lesions on T2*-weighted MR images, excluding lesions in the globus pallidum and the subarachnoid space, which are likely to represent calcification and adjacent pial blood vessels, respectively. Intracerebral lesions with a hemorrhagic component associated with tumors, arteriovenous malformations, cavernomas, and abscesses were also excluded. WMH on T2-weighted images was graded by using the scoring system of Fazekas et al 25 into 4 grades: grade 0 ϭ absent, 1 ϭ punctate, 2 ϭ early confluent, and 3 ϭ confluent. WMH of grade 2 or 3 was regarded as advanced WMH. MR images were evaluated by 2 of the authors (H.N., H.U.) separately without knowledge of the patients' clinical profiles, and the number of microbleeds and the grading scores of WMH were determined by consensus. In all patients, international normalized ratios (INRs) were evaluated by using blood taken before starting acute therapy. Hypertension was defined as systolic blood pressure of Ն140 mm Hg and diastolic blood pressure of Ն90 mm Hg before recurrence of stroke or occurring in patients currently undergoing medical treatment for hypertension. Diabetes mellitus was defined as a glycosylated hemoglobin A1c concentration of Ͼ5.8% or occurring in patients currently using hypoglycemic agents. Hypercholesterolemia was defined as a total cholesterol level of Ն220 mg/dL or occurring in patients currently undergoing cholesterol-lowering therapy. Whether patients had undergone antiplatelet therapy before occurrence of stroke was recorded.
All values are expressed as means Ϯ SD. Among ICH and cerebral infarction, the 2 (Table 2) .
Discussion
The present study demonstrated that the presence of cerebral microbleeds was associated with ICH independent of increased INR and hypertension in patients with cerebral infarction following atrial fibrillation-related cardioembolic infarction. Although some studies have been performed to determine whether the use of antiplatelet therapy is associated with the occurrence of ICH in patients with microbleeds, 13 this is the first study aimed at determining whether the presence of microbleeds is associated with recurrent hemorrhagic stroke in patients who had undergone warfarin treatment following atrial fibrillation-associated cardioembolic infarction. Although it has been established that warfarin treatment is effective for preventing cerebral embolism arising from atrial fibrillation, the most serious adverse event in atrial fibrillation is hemorrhage complication. An excess incidence of major bleeding (7% per year) in patients with nondisabling cerebral ischemia of presumed arterial origin and treated with oral anticoagulation led to early termination of the Stroke Prevention in Reversible Ischemia Trial (SPIRIT). 26 As for radiographic characteristics as risk factors for warfarin-related ICH, the presence of advanced leukoaraiosis has been reported. 22, 27 Gorter 27 assessed independent predictors of hemorrhage in 651 anticoagulated patients after cerebral ischemia in SPIRIT and reported that leukoaraiosis detected by CT, intensity of anticoagulation, and age older than 65 years are independent risk factors for bleeding in anticoagulated patients. Smith et al 22 compared radiographic and clinical characteristics of 26 patients with warfarin-related ICH following ischemic stroke with those of 56 controls, and they reported that the presence and severity of leukoaraiosis detected by CT were independent risk factors for poststroke warfarin-related ICH.
These results indicate that warfarin may trigger ICH in patients with severe disturbance of cerebral small arteries. In contrast, our results showed that the presence of microbleeds, but not advanced WMH, was an independent risk factor of poststroke warfarin-related ICH. This discrepancy may be explained by the pathologic difference between microbleeds and WMH. For instance, though both microbleeds and WMH are associated with small-vessel diseases and often coexist, microbleeds are a bleeding-prone small-vessel disease and WMH is an ischemic small-vessel disease. In fact, some previous studies have shown that the presence of microbleeds is a predictor of ICH in patients with no or mild leukoaraiosis. 7, 19 On the other hand, it was also revealed that patients with advanced leukoaraiosis but without microbleeds tend to be associated with ischemic stroke rather than ICH. 19 In a study using 3 autopsied brains, microbleeds were revealed to be associated with hemosiderin deposit that had been caused by a rupture of arteriosclerotic microvessels, supporting the notion that microbleeds are associated with fragility of blood vessels.
1 INR in the ICH group was much higher than that in the cerebral infarction group, and INR was an independent risk factor for ICH in our study. Excess anticoagulation itself may have resulted in the occurrence of ICH, whereas hemorrhagic diathesis may have predisposed to microbleeds and ICH with the use of warfarin.
The results of the present study also showed that the fre- quency of hypertension was higher in patients with ICH than in patients with cerebral infarction and was an independent risk factor of warfarin-related ICH. Although it has been shown that hypertension is a major risk factor of microbleeds 1, 4, 15, 18, 28, 29 and ICH, it remains to be clarified whether hypertension management in the presence of microbleeds prevents the occurrence of ICH. Strict management of hypertension in anticoagulated patients with microbleeds is important in preventing the occurrence of ICH, but further studies are needed to confirm this.
Our study has some limitations. Because we could see the hematoma in patients with ICH when evaluating microbleeds on T2*-weighted MR images, this study was not a completely blind trial; therefore, bias could not be avoided. In addition, the duration of anticoagulant medication was not recorded in the present study. It remains to be determined whether the duration of anticoagulant medication affects the presence of microbleeds and the occurrence of ICH. It would also be informative to have included a control group of patients who were not treated with warfarin to estimate to what extent warfarin increases the risk of ICH in patients with microbleeds above their untreated incidence. In addition, patients with arterial embolic strokes who are not anticoagulated would be an additional and important group. Further studies are needed to clarify such issues.
Conclusions
The results of the present study suggest that evaluation of the presence of cerebral microbleeds as a risk factor for ICH in patients being treated with warfarin deserves study in a blind and controlled prospective therapeutic trial.
